BVS:NSD-Bioventus Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 9.69

Change

+0.03 (+0.31)%

Market Cap

USD 0.52B

Volume

0.60M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-28 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

+0.69 (+1.00%)

USD 27.98B
PODD Insulet Corporation

+3.42 (+1.48%)

USD 15.15B
BRKR Bruker Corporation

+0.93 (+1.44%)

USD 9.75B
MASI Masimo Corporation

-0.20 (-0.18%)

USD 6.15B
TMDX TransMedics Group Inc

+2.28 (+1.53%)

USD 4.66B
PRCT Procept Biorobotics Corp

+0.72 (+0.90%)

USD 4.00B
AXNX Axonics Modulation Technologie..

+0.13 (+0.19%)

USD 3.52B
QDEL Quidel Corporation

+0.67 (+1.50%)

USD 2.76B
TNDM Tandem Diabetes Care Inc

+0.21 (+0.48%)

USD 2.69B
LIVN LivaNova PLC

-0.21 (-0.43%)

USD 2.66B

ETFs Containing BVS

FKU:LSE First Trust United Kingdo.. 2.64 % 0.00 %

+26.25 (+1.11%)

USD 6.70M
FKUD:LSE First Trust United Kingdo.. 2.64 % 0.00 %

+19.25 (+1.11%)

USD 2.32M
XXSC:LSE db x-trackers MSCI Europe.. 0.49 % 0.00 %

+54.75 (+1.11%)

USD 1.94B
FKU First Trust United Kingdo.. 0.00 % 0.80 %

+0.21 (+1.11%)

USD 0.07B
FNDC Schwab Fundamental Intern.. 0.00 % 0.39 %

+0.23 (+1.11%)

USD 3.25B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 83.87% 87% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 83.87% 87% B+ 94% A
Trailing 12 Months  
Capital Gain 175.28% 96% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 175.28% 96% N/A 98% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 7.93% 60% D- 64% D
Dividend Return 7.93% 60% D- 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 99.45% 30% F 17% F
Risk Adjusted Return 7.98% 65% D 45% F
Market Capitalization 0.52B 72% C 61% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector